Serum free insulin-like growth factor-i in growth hormonedeficient adults before and after growth hormone replacement
|
|
- Veronica Williams
- 6 years ago
- Views:
Transcription
1 European Journal of Endocrinology (1997) ISSN Serum free insulin-like growth factor-i in growth hormonedeficient adults before and after growth hormone replacement C Skjærbæk 1, N Vahl 2, J Frystyk 1, T B Hansen 3, J O L Jørgensen 2, C Hagen 3, J S Christiansen 2 and H Ørskov 1 1 Institute of Experimental Clinical Research, Medical Research Laboratories, Aarhus University, Denmark, 2 Medical Department M, Aarhus Kommunehospital, Aarhus, Denmark and 3 Department of Endocrinology M, Odense University Hospital, Odense, Denmark (Correspondence should be addressed to C Skjærbæk, Medical Research Laboratories, Aarhus Kommunehospital, Building 3, 8000 Aarhus C, Denmark) Abstract The objective of the present study was to compare fasting levels of free IGF-I in serum from patients with adult onset growth hormone deficiency (GHD) and from healthy volunteers, and to examine the effect of GH replacement therapy in GHD on serum free IGF-I. Free IGF-I was measured using separation of free IGF-I by ultrafiltration in serum samples from 42 healthy volunteers and 27 patients with GHD, in the latter before and after 1 year of treatment with GH (2 IU/m 2 )(n= 13) or placebo (n = 14). Free IGF-I was significantly decreased in patients with GHD ( ng/l (mean S.E.M.), range ng/l) compared with controls ( ng/l, range ng/l; P = ). Total IGF-I was mg/l (GHD) and mg/l (controls) (P < ). The ratio of free over total IGF-I was increased in GHD to % compared with % in controls (P = 0.04). In both GHD and controls, free IGF-I correlated significantly (P < 0.05) with total IGF-I (GHD r = 0.78; controls r = 0.42), IGFBP-1 (GHD r = ¹0.67; controls r = ¹0.46) and the molar ratio of total IGF-I over IGFBP-3 (GHD r = 0.58; controls r = 0.62). After 1 year of GH treatment, free IGF-I was increased to ng/l (P = 0.003) and total IGF-I was increased to mg/l (P = 0.006) both of which values were greater than those in healthy volunteers. There were no changes in free or total IGF-I in the placebo-treated group. In conclusion, levels of free IGF-I are decreased in GHD, but measurements of free IGF-I in a single, fasting serum sample do not offer a better separation of patients with GHD from individuals with normal GH status than can be achieved by measurement of total IGF-I. One year of treatment with 2 IU/m 2 GH caused an increase of serum free IGF-I to supraphysiological levels. European Journal of Endocrinology Introduction Serum levels of total insulin-like growth factor-i (IGF-I) are mainly under the control of growth hormone (GH), and serum levels of IGF-I are decreased in GH deficiency (GHD) (1 4) and increase after GH replacement (5, 6). Measurements of serum total IGF-I are therefore useful in the assessment of GH secretion in GHD (2, 7) and in the evaluation of GH replacement (5, 6). There is, however, a considerable overlap in serum total IGF-I levels between GH-deficient adults and in normal healthy individuals (3, 4). Measurements of serum total IGF-I can therefore be used only as a screening procedure, but cannot replace the more laborious GHprovocative tests in the diagnosis of GHD (3). The vast majority of circulating IGF-I is bound to six specific IGF-binding proteins (IGFBPs -1 to -6). We have recently validated a method for the determination of the free, unbound fraction of circulating IGF-I using ultrafiltration, and found that in normal, fasting adults approximately % is in the free form (8). The physiological significance of this unbound moiety remains unclear, but it has been proposed to reflect the bioactivity of IGF-I in serum. Levels of free IGF-I could therefore be expected to be low in GHD and increase after GH replacement, and might add further information, useful in monitoring the clinical effect of GH. To investigate this we have compared levels of free, fasting IGF-I in 27 GH-deficient patients and a control group of 42 healthy volunteers. Furthermore, we have measured free IGF-I after 1 year of treatment with either GH or placebo in the GH-deficient patients. Subjects and methods Subjects and design Twenty-seven patients with adult onset GHD secondary to pituitary pathology were included in the study. None of the patients had been treated with GH before the study. The diagnosis of GHD was confirmed by a GH-stimulation test with insulin. Detailed data on the patients have been provided in a previous publication (9). The patients were 1997 Society of the European Journal of Endocrinology
2 EUROPEAN JOURNAL OF ENDOCRINOLOGY (1997) 137 Free IGF-I in GH deficiency 133 allocated randomly to groups to receive 1 year of treatment with either placebo (n = 14) or GH (Norditropin, Novo Nordisk A/S, Bagsværd, Denmark) in a dosage of 2 IU/m 2 body surface per day (n = 13). Fasting blood samples were obtained before the start of treatment and after 1 year. For comparison fasting blood samples were obtained from 42 healthy volunteers. Informed consent was obtained from all participants and the study was approved by the Danish National Health authorities and the regional ethics committee. Assays IGFBP-1, IGFBP-3, and insulin were measured by commercial assays: IGFBP-1 by ELISA (Medix Biochemica, Kainainen, Finland), IGFBP-3 by RIA (Diagnostic System Laboratories Inc., Webster, TX, USA) and insulin by RIA (Novo Nordisk A/S). Total IGF-I was determined by an in-house, non-competitive time-resolved immunofluorimetric assay (TR-IFMA) after acid ethanol extraction of serum as described previously (10). Free IGF-I was separated from bound IGF-I by ultrafiltration (8): serum samples were diluted 1 : 11 in Krebs Ringer bicarbonate buffer containing 5% human serum albumin (ph = 7.4), 600 ml of the dilution was applied to a YMT-30 ultrafiltration membrane mounted in an MPS-1 supporting device (both Amicon Division, W R Grace and Co., Beverly, MA, USA) and centrifuged at 300 g at 37 C in triplicate. We have previously demonstrated that dilution of serum from normal individuals and those with GHD before centrifugation can be undertaken without altering the concentration of free IGF-I (8). After appropriate dilution of the filtrate, the concentration of free IGF-I was measured directly in the TR-IFMA. All samples from one individual were run in the same assay. The limit of detection of free IGF-I is 27.5 ng/l and the average intraand interassay coefficients of variation were 14% and 17% respectively. Statistics Data showing normal distribution are expressed as mean S.E.M., otherwise as median and percentiles. The Mann Whitney non-parametric test was used to compare groups. Wilcoxon s non-parametric test for paired data was used to compare effect of treatment. Fisher s exact test was used to compare proportions. Correlations were performed on log-transformed data when appropriate. P values less than 0.05 were considered significant. All statistical tests were performed using the SOLO statistical package (BMDP Statistical Software, Los Angeles, CA, USA). Results GH-deficient patients compared with normal volunteers The results are summarized in Table 1. Free IGF-I was decreased in the GH-deficient group compared with the controls, but there was a considerable overlap between the two groups, as shown in Fig. 1A. The same was true for total IGF-I (Fig. 1B) and IGFBP-3. Ten GH-deficient patients (37%) had a serum concentration of free IGF-I below the 5th percentile of the controls (400 ng/l), 19 (70%) had a serum concentration of total IGF-I below this level (94 mg/l) and 19 (70%) had a serum IGFBP-3 below it (2220 mg/l). Serum IGFBP-1 was increased in the GH-deficient group compared with the controls, whereas there was no difference in levels of fasting insulin. In the controls free IGF-I correlated positively with total IGF-I (r = 0.42, P = 0.006) (Fig. 2A and B) and with the molar ratio of IGF-I over IGFBP-3 (r = 0.37, P = ), and correlated negatively with IGFBP-1 (r = ¹0.46, P = 0.002) (Fig. 2C and D), whereas there were no correlations between free IGF-I and body mass index (BMI), IGFBP-3 or insulin. In the GH-deficient group, free IGF-I was found to be positively correlated to total IGF-I (r = 0.78, P < ) (Fig. 2B), IGFBP-3 Table 1 Characteristics and results for all participants. Values are mean S.E.M. or median (10 90 percentiles). GHD (n ¼ 27) Controls (n ¼ 42) P Male/female 18/9 20/ Age (years) 47 (31 54) 32 (28 52) BMI (kg/m 2 ) Total IGF-I (mg/l) < Free IGF-I (ng/l) Free over total IGF-I (%) IGFBP-3 (mg/l) < IGF-I over IGFBP ( ) 0.20 ( ) 0.09 IGFBP-1 (mg/l) 3.6 ( ) 2.5 ( ) Insulin (mu/l) 8 (4 18) 10 (6 16) 0.21
3 134 C Skjærbæk and others EUROPEAN JOURNAL OF ENDOCRINOLOGY (1997) 137 Figure 1 Individual values of fasting free IGF-I (A), total IGF-I (B), and free over total IGF-I ratio (C) in 27 patients with GHD (W) and 42 normal individuals (X). Horizontal bars represent averages. (r =0.58, P= 0.002) and the molar ratio of total IGF-I over IGFBP-3 (r = 0.59, P = ), and negatively correlated to IGFBP-1 (r = ¹0.67, P = ) (Fig. 2D). There were no correlations between free IGF-I and BMI or insulin. Effects of GH replacement There were no differences in BMI, age, insulin, IGFBP-1, IGFBP-3, free or total IGF-I between the GH-treated group and the placebo group before treatment (data not shown). GH treatment caused a significant increase in free IGF-I from ng/l to ng/l (P = 0.003; Fig. 3A). Total IGF-I increased from mg/l to mg/l (P = 0.006; Fig. 3C), IGFBP-3 increased from mg/l to mg/l (P = 0.003) and the molar ratio of total IGF-I over IGFBP-3 increased from 0.17 to 0.44 (P < ). Total IGF-I increased in all 12 patients receiving GH and free IGF-I increased in 11 of the 12. There was no change in the ratio of free IGF-I over total IGF-I (before: 0.87% ( %); after: 0.89% ( %); P = 0.58) and there was no change in IGFBP-1 (before: 3.5 mg/l ( mg/l); after: 1.5 mg/l ( mg/l) P = 0.12). Fasting serum insulin increased from 10 2mU/l to 16 3 mu/l (P = 0.016). After 1 year of GH replacement, both total and free IGF-I levels were significantly (P < ) increased compared with those in the control group. There was no difference in IGFBP-3 between the control group and the GHtreated group (P = 0.14). In the placebo-treated group, there were no significant changes in free or total IGF-I (Fig. 3B, D), IGFBP-1, IGFBP-3 or insulin (data not shown). Discussion Serum total IGF-I and serum IGFBP-3 are decreased in adult GHD, but the levels of both peptides overlap with those of normal individuals, hence measurements of serum total IGF-I and IGFBP-3 are poor diagnostic tests of adult GHD (3, 4). In this study, we have examined levels of free IGF-I in a group of GH-deficient patients, using separation of free and bound IGF-I by ultrafiltration. As expected, levels of free IGF-I were significantly decreased in the GHdeficient patients. However, the levels in those patients overlapped with levels in the controls, and free IGF-I was actually decreased to a lesser degree than total IGF-I. Measurements of free IGF-I in a single, fasting serum sample therefore did not offer a better separation of adult patients with GHD from healthy individuals than could be achieved by measurement of total IGF-I or IGFBP-3. Fasting serum samples were obtained in this study, to minimize the possible influence of varying levels of insulin and, thereby, IGFBP-1. It is likely that there is a diurnal variation of free IGF-I, but the relation between a single fasting measurement and 24-h levels of free IGF-I is unknown. Hasegawa et al. (11), using a direct IRMA for free IGF-I, found that 94% of children and adolescents with complete GHD and 67% of children with partial GHD had levels of free IGF-I below the 5th percentile of an age-matched normal population sample. In contrast to the findings of our study, there was no difference in the ratio of free IGF-I over total IGF-I between the GHD group and the control group in that study. It was not stated whether fasting serum samples were obtained.
4 EUROPEAN JOURNAL OF ENDOCRINOLOGY (1997) 137 Free IGF-I in GH deficiency 135 Figure 2 Linear correlation between individual values of fasting free IGF-I and total IGF-I in normal volunteers (A) and patients with GHD (B); and free IGF-I and IGFBP-1 in healthy volunteers (C) and patients with GHD (D). Although there was no statistical difference in the age of the GHD group and the control group in the present study, the latter group was not age-matched to the GHD group, in that the control group contained several individuals in the age range years, and this may have contributed to the difference in free IGF-I between the GHD group and the control group (8). The GHD group had a considerably greater BMI than the control group. Although we did not find any correlation between free IGF-I and BMI in this study, we have previously shown that the level of free IGF-I is increased in obese individuals (BMI > 25 kg/m 2 ) compared with that in normal subjects (BMI < 25 kg/m 2 ) (12). However, in that study the obese groups were characterized by hyperinsulinaemia and decreased levels of IGFBP-1 and, using multiple regression analysis, it was shown that IGFBP-1 was the only important determinant for free IGF-I (12). In the present study, the patients with GHD had significantly increased levels of IGFBP-1, and it is therefore difficult to predict which possible influence the difference in BMI may have had on free IGF-I. In contrast to IGFBP-1 concentrations, there were no significant differences in levels of insulin, the principal regulator of IGFBP-1, confirming that IGFBP-1 is increased relative to insulin in GHD (13). The molar ratio of total IGF-I over IGFBP-3 has been proposed to reflect free or easily dissociable IGF-I (14). In this study, we found a correlation between free IGF-I and this molar ratio, both in the GHD patients and in the controls. In the controls, this correlation was weak (r=0.37) and there was no difference in the molar ratio between the two groups, suggesting that this gives only a crude estimate of free IGF-I. We have previously demonstrated significant inverse relationships between serum levels of IGFBP-1 and free IGF-I in human obesity (12), during an oral glucosetolerance test and during short-term fasting (8), in each
5 136 C Skjærbæk and others EUROPEAN JOURNAL OF ENDOCRINOLOGY (1997) 137 Figure 3 Individual changes in fasting free IGF-I (upper panel) and total IGF-I (lower panel) during 1 year of GH replacement (A and C) or placebo (B and D). case without significant changes in total IGF-I. The observed significant inverse correlations between free IGF-I and IGFBP-1 both in the GH-deficient patients and the controls also found in this study are supportive for the view that IGFBP-1 is an important determinant of free IGF-I, and thereby of IGF-I bioactivity (15 19). In the GHD group treated with GH, levels of free and total IGF-I were significantly increased. Free IGF-I and total IGF-I were increased to the same degree, as there was no change in the ratio of free over total IGF-I. Both free and total IGF-I were increased to levels exceeding those of the control group i.e. to supraphysiological levels. This is in agreement with the view that the GH replacement dose used in this study (2 IU/m 2 per day) and in many other clinical studies to date, is probably too high (6, 20 23). This notion is based on both serum measurements and the frequency of side-effects (21, 23). In this regard, our free IGF-I data emphasize that the GH dose requirement in adults is lower, but whether or not measurements of free IGF-I will provide a useful tool for titration of the optimal GH dose remains to be investigated. In conclusion, we found that free IGF-I is significantly decreased in adult GHD, but measurement of free IGF-I in a single fasting sample is not a better marker for GHD in adults than measurement of total IGF-I or IGFBP-3. After 1 year of replacement therapy, free IGF-I was increased in parallel with total IGF-I. Whether measurements of free IGF-I is a useful tool in the monitoring of GH replacement therapy needs further studies with GH doses in a more physiological range. Acknowledgements We are indebted to Kirsten Nyborg Rasmussen, Susanne Sørensen, Inga Bisgaard, and Joan Hansen for skilled technical assistance. GH and placebo were generously supplied by Novo Nordisk A/S, Bagsværd, Denmark. Aarhus University Research Foundation is thanked for financial support of this study.
6 EUROPEAN JOURNAL OF ENDOCRINOLOGY (1997) 137 Free IGF-I in GH deficiency 137 References 1 Furlanetto RW, Underwood LE, Van Wyk JJ & D Ercole AJ. Estimation of somatomedin-c levels in normals and patients with pituitary disease by radioimmunoassay. Journal of Clinical Investigation Bates AS, Evans AJ, Jones P & Clayton RN. Assessment of GH status in adults with GH deficiency using serum growth hormone, serum insulin-like growth factor-i and urinary growth hormone excretion. Clinical Endocrinology Hoffman DM, O Sullivan AJ, Baxter RC & Ho KK. Diagnosis of growth-hormone deficiency in adults. Lancet Baum HB, Biller BM, Katznelson L, Oppenheim DS, Clemmons DR, Cannistraro KB et al. Assessment of growth hormone (GH) secretion in men with adult-onset GH deficiency compared with that in normal men a clinical research center study. Journal of Clinical Endocrinology and Metabolism Jørgensen JOL, Flyvbjerg A, Lauritzen T, Alberti KG, Ørskov H & Christiansen JS. Dose response studies with biosynthetic human growth hormone (GH) in GH-deficient patients. Journal of Clinical Endocrinology and Metabolism Møller J, Jørgensen JOL, Lauersen T, Frystyk J, Næraa RW, Ørskov H etal. Growth hormone dose regimens in adult GH deficiency: effects on biochemical growth markers and metabolic parameters. Clinical Endocrinology de Boer H, Blok GJ & van der Veen EA. Clinical aspects of growth hormone deficiency in adults. Endocrine Review Frystyk J, Skjærbæk C, Dinesen B & Ørskov H. Free insulin-like growth factors (IGF-I and IGF-II) in human serum. FEBS Letters Hansen TB, Vahl N, Jørgensen JOL, Christiansen JS & Hagen C. Whole body and regional soft tissue changes in growth hormone deficient adults after one year of growth hormone treatment: a double-blind, randomized, placebo-controlled study. Clinical Endocrinology Frystyk J, Dinesen B & Ørskov H. Non-competitive time-resolved immunofluorimetric assay for determination of human insulinlike growth factor I and II. Growth Regulation Hasegawa Y, Hasegawa T, Takada M & Tsuchiya Y. Plasma free insulin-like growth factor I concentrations in growth hormone deficiency in children and adolescents. European Journal of Endocrinology Frystyk J, Vestbo E, Skjærbæk C, Mogensen CE & Ørskov H. Free insulin-like growth factors in human obesity. Metabolism (suppl 4) Hilding A, Brismar K, Degerblad M, Thoren M & Hall K. Altered relation between circulating levels of insulin-like growth factorbinding protein-1 and insulin in growth hormone-deficient patients and insulin-dependent diabetic patients compared with that in healthy subjects. Journal of Clinical Endocrinology and Metabolism Juul A, Main K, Blum WF, Lindholm J, Ranke MB & Skakkebæk NE. The ratio between serum levels of insulin-like growth factor (IGF)-I and the IGF binding proteins (IGFBP-1, 2 and 3) decreases with age in healthy adults and is increased in acromegalic patients. Clinical Endocrinology Cox GN, McDermott MJ, Merkel E, Stroh CA, Ko SC, Squires CH et al. Recombinant human insulin-like growth factor (IGF)-binding protein-1 inhibits somatic growth stimulated by IGF-I and growth hormone in hypophysectomized rats. Endocrinology Rajkumar K, Barron D, Lewitt MS & Murphy LJ. Growth retardation and hyperglycemia in insulin-like growth factor binding protein-1 transgenic mice. Endocrinology Lewitt MS, Denyer GS, Cooney GJ & Baxter RC. Insulin-like growth factor-binding protein-1 modulates blood glucose levels. Endocrinology Taylor AM, Dunger DB, Preece MA, Holly JM, Smith CP, Wass JA et al. The growth hormone-independent insulin-like growth factor-i binding protein BP-28 is associated with serum insulin-like growth factor-i inhibitory bioactivity in adolescent insulindependent diabetics. Clinical Endocrinology Baxter RC. Insulin-like growth factor (IGF) binding proteins: the role of serum IGFBPs in regulating IGF availability. Acta Paediatrica Scandinavica (Suppl) Wollmann HA, Schonau E, Blum WF, Meyer F, Kruse K & Ranke MB. Dose-dependent responses in insulin-like growth factors, insulin-like growth factor-binding protein-3 and parameters of bone metabolism to growth hormone therapy in young adults with growth hormone deficiency. Hormone Research de Boer H, Blok GJ, Voerman B, de Vries P, Popp Snijders C & van der Veen E. The optimal growth hormone replacement dose in adults, derived from bioimpedance analysis. Journal of Clinical Endocrinology and Metabolism Shalet SM & Holmes SJ. Growth hormone replacement in adults. British Medical Journal de Boer H, Blok GJ, Popp Snijders C, Stuurman L, Baxter RC & van der Veen E. Monitoring of growth hormone replacement therapy in adults, based on measurement of serum markers. Journal of Clinical Endocrinology and Metabolism Received 6 September 1996 Accepted 28 April 1997
GH stimulation tests: evaluation of GH responses to heat test versus insulin-tolerance test
European Journal of Endocrinology (1998) 139 605 610 ISSN 0804-4643 GH stimulation tests: evaluation of GH responses to heat test versus insulin-tolerance test Sanne Fisker 1, Jens Otto Jørgensen 1,2,
More informationFree Rather than Total Circulating Insulin-Like Growth Factor-I Determines the Feedback on Growth Hormone Release in Normal Subjects
0021-972X/05/$15.00/0 The Journal of Clinical Endocrinology & Metabolism 90(1):366 371 Printed in U.S.A. Copyright 2005 by The Endocrine Society doi: 10.1210/jc.2004-0039 Free Rather than Total Circulating
More informationFailure of IGF-I and IGFBP-3 to diagnose growth hormone insuyciency
Arch Dis Child 999;8:3 7 3 Failure of IGF-I and IGFBP-3 to diagnose growth hormone insuyciency H Mitchell, M T Dattani, V Nanduri, P C Hindmarsh, M A Preece, C G D Brook London Centre for Paediatric Endocrinology,
More informationX/00/$03.00/0 Vol. 85, No. 11 The Journal of Clinical Endocrinology & Metabolism Copyright 2000 by The Endocrine Society
0021-972X/00/$03.00/0 Vol. 85, No. 11 The Journal of Clinical Endocrinology & Metabolism Printed in U.S.A. Copyright 2000 by The Endocrine Society The Effect of Four Weeks of Supraphysiological Growth
More informationFASTING CONSTITUTES A VERY robust stimulus for
0021-972X/03/$15.00/0 The Journal of Clinical Endocrinology & Metabolism 88(7):3292 3298 Printed in U.S.A. Copyright 2003 by The Endocrine Society doi: 10.1210/jc.2002-021983 The Effect of Growth Hormone
More informationDose-response study of GH effects on circulating IGF-I and IGFBP-3 levels in healthy young men and women
Dose-response study of GH effects on circulating IGF-I and IGFBP-3 levels in healthy young men and women E. GHIGO, 1 G. AIMARETTI, 1 M. MACCARIO, 1 G. FANCIULLI, 2 E. ARVAT, 1 F. MINUTO, 3 G. GIORDANO,
More informationTitle: Growth Hormone Treatment for Adult Growth Hormone Deficiency
Title: Growth Hormone Treatment for Adult Growth Hormone Deficiency Date: 05 October, 2007 Context and policy issues: Growth hormone (GH) is produced by the pituitary gland and plays a role in increasing
More informationPFIZER INC. THERAPEUTIC AREA AND FDA APPROVED INDICATIONS: See USPI.
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.
More informationEuropean Journal of Endocrinology (2003) ISSN
European Journal of Endocrinology (2003) 149 117 122 ISSN 0804-4643 CLINICAL STUDY Comparison between insulin tolerance test, growth hormone (GH)-releasing hormone (GHRH), GHRH plus acipimox and GHRH plus
More informationRelationship between Plasma (IGF-l) Levels and Body Mass. Insulin-like Growth Factor Index (BMI) in Adults
Endocrine Journal 1993, 40 (1), 41-45 Relationship between Plasma (IGF-l) Levels and Body Mass Insulin-like Growth Factor Index (BMI) in Adults HIROYuKI YAMAMOTO AND YUZURU KATO First Division, Department
More informationEuropean Journal of Endocrinology (2000) ISSN
European Journal of Endocrinology (2000) 142 243 253 ISSN 0804-4643 CLINICAL STUDY Diagnostic efficiency of serum IGF-I, IGF-binding protein-3 (IGFBP-3), IGF-I/IGFBP-3 molar ratio and urinary GH measurements
More informationChanges Children. in Serum Levels of IGF-l and with Chronic Renal Failure# IGFBP-3 NECLA BUYAN*, PEYAMI CINAZ***, ENVER HASANOGLU*, AND ZELAL BIRCAN*
Endocrine Journal 1995, 42(3), 429-433 NOTE Changes Children in Serum Levels of IGF-l and with Chronic Renal Failure# IGFBP-3 in NECLA BUYAN*, PEYAMI CINAZ***, ENVER HASANOGLU*, AND ZELAL BIRCAN* NAHIDE
More informationESTIMATES OF GH secretion in normal adult males have
0021-972X/99/$03.00/0 Vol. 84, No. 11 The Journal of Clinical Endocrinology & Metabolism Printed in U.S.A. Copyright 1999 by The Endocrine Society Route of Estrogen Administration Helps to Determine Growth
More informationMetabol ic Actions of Growth Hormone in Man
Endocrine Journal 1996, 43 (Suppl), S57-S63 Metabol ic Actions of Growth Hormone in Man KEN K Y HO, ANTHONY J O'SULLIVAN, AND DAVID M HOFFMAN Garvan Institute of Medical Research St. Vincent's Hospital,
More informationGROWTH HORMONE DEFICIENCY AND OTHER INDICATIONS FOR GROWTH HORMONE THERAPY ADULT
1. Medical Condition GROWTH HORMONE DEFICIENCY AND OTHER INDICATIONS FOR GROWTH HORMONE THERAPY ADULT Growth Hormone Deficiency and other indications for growth hormone therapy (adult). 2. Diagnosis A.
More informationMelatonin and Growth Hormone Deficiency: A Contribution to the Evaluation of Neuroendocrine Disorders
Melatonin and Growth Hormone Deficiency: A Contribution to the Evaluation of Neuroendocrine Disorders Fideleff G., Suárez M., Boquete HR, Azaretzky M., Sobrado P., Brunetto O*, Fideleff HL Endocrinology
More informationActa Diabetol (1998) 35: Springer-Verlag 1998
Acta Diabetol (1998) 35: 85 90 Springer-Verlag 1998 ORIGINAL A. M. Cortizo P. D. K. Lee N. V. Cédola H. Jasper J. J. Gagliardino Relationship between non-enzymatic glycosylation and changes in serum insulin-like
More informationTransitional care of GH deficiency: when to stop GH therapy
European Journal of Endocrinology (2004) 151 S61 S65 ISSN 0804-4643 Transitional care of GH deficiency: when to stop GH therapy M O Savage, W M Drake, P V Carroll and J P Monson Department of Endocrinology,
More informationA highly sensitive and specific assay for determination of IGF-I bioactivity in human serum
Am J Physiol Endocrinol Metab 284: E1149 E1155, 2003. First published February 25, 2003; 10.1152/ajpendo.00410.2002. A highly sensitive and specific assay for determination of IGF-I bioactivity in human
More informationATHLETES & PRESCRIBING PHYSICIANS PLEASE READ
ATHLETES & PRESCRIBING PHYSICIANS PLEASE READ USADA can grant a Therapeutic Use Exemption (TUE) in compliance with the World Anti- Doping Agency International Standard for TUEs. The TUE application process
More informationPro- and mature IGF-II during diet-induced weight loss in obese subjects
European Journal of Endocrinology (2005) 153 861 869 ISSN 0804-4643 CLINICAL STUDY Pro- and mature IGF-II during diet-induced weight loss in obese subjects Ulrick Espelund, Jens Meldgaard Bruun, Bjørn
More informationHumatrope*, Norditropin*, Genotropin, Nutropin, Nutropin AQ, Omnitrope, Saizen
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.08.11 Subject: Growth Hormone Adult Page: 1 of 6 Last Review Date: December 5, 2014 Growth Hormone Adult
More informationSUPPLEMENTARY DATA. Supplementary Table S1. Clinical characteristics of the study subjects.*
Supplementary Table S1. Clinical characteristics of the study subjects.* T2D ND n (F/M) 66 (21/45) 25 (7/18) Age (years) 61.8 ± 6.9 49.4 ± 7.3 # Body weight (kg) 95 ± 16 105 ± 13 # Body mass index (kg.
More informationNo effect of exercise on insulin-like growth factor (IGF)-1, insulin and glucose in young women participating in a 16-week randomized controlled trial
University of North Florida UNF Digital Commons Nutrition and Dietetics Faculty Publications Department of Nutrition and Dietetics 11-2010 No effect of exercise on insulin-like growth factor (IGF)-1, insulin
More informationDiabetologia 9 Springer-Verlag 1982
Diabetologia (1982) 22:245-249 Diabetologia 9 Springer-Verlag 1982 Twenty-Four Hour Profiles of Plasma C-Peptide in Type 1 (Insulin-Dependent) Diabetic Children G. A. Werther 1 *, R. C. Turner 2, P. A.
More informationNo effect of growth hormone administration on substrate oxidation during exercise in young, lean men
J Physiol 567.3 (2005) pp 1035 1045 1035 No effect of growth hormone administration on substrate oxidation during exercise in young, lean men Mette Hansen 1,RikkeMorthorst 1,BennyLarsson 2,Rolf Dall 3,Allan
More informationGrowth hormone treatment of subfertile males*
FERTILITY AND STERILITY Copyright 1996 American Society for Reproductive Medicine Printed on acid free paper in U. S. A. Growth hormone treatment of subfertile males* Per Ovesen, M.D. H Jens Otto Lunde
More informationIT IS WIDELY recognized that the diagnosis of GH deficiency
0021-972X/97/$03.00/0 Vol. 82, No. 2 Journal of Clinical Endocrinology and Metabolism Printed in U.S.A. Copyright 1997 by The Endocrine Society Biochemical s in the Diagnosis of Childhood Growth Hormone
More informationRequest for Prior Authorization Growth Hormone (Norditropin
Request for Prior Authorization Growth Hormone (Norditropin, Nutropin/AQ ) Website Form www.highmarkhealthoptions.com Submit request via: Fax - 1-855-476-4158 All requests for Growth Hormone require a
More informationTesamorelin Clinical Data Overview Jean-Claude Mamputu, PhD Senior Medical Advisor, Theratechnologies
Tesamorelin Clinical Data Overview Jean-Claude Mamputu, PhD Senior Medical Advisor, Theratechnologies Copyright 2016. All Rights Reserved. Property of Theratechnologies Inc. Mechanism of Action of Tesamorelin
More informationReview Article. Insulin like Growth Factors and Growth Hormone Deficiency
Review Article Insulin like Growth Factors and Growth Hormone Deficiency Sangeeta Yadav Sriram Krishnamurthy Insulin-like growth factors (IGFs) are polypeptides that act as endocrine mediators of growth
More informationLong-term effects of growth hormone (GH) on body fluid distribution in GH deficient adults: a four months double blind placebo controlled trial
European Journal of Endocrinology (1999) 140 11 16 ISSN 0804-4643 Long-term effects of growth hormone (GH) on body fluid distribution in GH deficient adults: a four months double blind placebo controlled
More informationGrowth Hormone!gents. WA.PHAR.50 Growth Hormone Agents
Growth Hormone!gents WA.PHAR.50 Growth Hormone Agents Background: Human growth hormone, also known as somatotropin, is produced in the anterior lobe of the pituitary gland. This hormone plays an important
More informationInsulin-like growth factor-i: marker for diagnosis of acromegaly and monitoring the efficacy of treatment
European Journal of Endocrinology (2003) 148 S15 S20 ISSN 0804-4643 Insulin-like growth factor-i: marker for diagnosis of acromegaly and monitoring the efficacy of treatment Georg Brabant Department of
More informationX/01/$03.00/0 Vol. 86, No. 3 The Journal of Clinical Endocrinology & Metabolism Copyright 2001 by The Endocrine Society
0021-972X/01/$03.00/0 Vol. 86, No. 3 The Journal of Clinical Endocrinology & Metabolism Printed in U.S.A. Copyright 2001 by The Endocrine Society Long-Term Effects of Continuous Subcutaneous Infusion Versus
More informationACROMEGALY IS A rare disorder usually caused by a
0021-972X/05/$15.00/0 The Journal of Clinical Endocrinology & Metabolism 90(10):5627 5631 Printed in U.S.A. Copyright 2005 by The Endocrine Society doi: 10.1210/jc.2005-0531 Cotreatment of Acromegaly with
More informationIntroduction. N Vahl 1, JOL Jùrgensen 1,5, TB Hansen 2, IB Klausen 3, A-G Jurik 4, C Hagen 2 and JS Christiansen 1,5
International Journal of Obesity (1998) 22, 529 ±536 ß 1998 Stockton Press All rights reserved 0307±0565/98 $12.00 http://www.stockton-press.co.uk/ijo The favourable effects of growth hormone (GH) substitution
More informationAssociation between serum IGF-1 and diabetes mellitus among US adults
Diabetes Care Publish Ahead of Print, published online July 16, 2010 Association between serum IGF-1 and diabetes mellitus among US adults Running title: Serum IGF-1 and diabetes mellitus Srinivas Teppala
More informationPFIZER INC. THERAPEUTIC AREA AND FDA APPROVED INDICATIONS: See USPI.
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.
More informationGrowth hormone therapy for short stature in adolescents the experience in the University Medical Unit, National Hospital of Sri Lanka
Growth hormone therapy for short stature in adolescents Growth hormone therapy for short stature in adolescents the experience in the University Medical Unit, National Hospital of Sri Lanka K K K Gamage,
More informationDose-, IGF-I- and sex-dependent changes in lipid profile and body composition during GH replacement therapy in adult onset GH deficiency
European Journal of Endocrinology (2004) 150 671 679 ISSN 0804-4643 CLINICAL STUDY Dose-, IGF-I- and sex-dependent changes in lipid profile and body composition during GH replacement therapy in adult onset
More informationbiosynthetic human growth hormone in man A double-blind cross-over study
Serum profiles and short-term metabolic effect of pituitary and authentic biosynthetic human growth hormone in man A double-blind cross-over study J. O. L. J\l=o/\rgensen, A. Flyvbjerg, J. Dinesen H. Lund,
More informationGrowth Hormone Possible to Detect?
Growth Hormone Possible to Detect? GH The most expensive, most fashionable and least understood of the new athletic drugs. (Underground Steroid Handbook 1983) Could be but does it work? GH increases muscle
More informationAetna Better Health of Virginia
Genotropin Nutropin Serostim Zomacton Humatrope Omnitrope Zorbtive somatropin Norditropin Saizen General Criteria for Approval: Omnitrope vial formulation is the preferred Growth Hormone product; consideration
More informationR ecombinant growth hormone (GH) treatment is recommended
126 ORIGINAL ARTICLE The investigation of short stature: a survey of practice in Wales and suggested practical guidelines C Evans, J W Gregory, on behalf of the All Wales Clinical Biochemistry Audit Group...
More informationThings you need to know about the Normal Distribution. How to use your statistical calculator to calculate The mean The SD of a set of data points.
Things you need to know about the Normal Distribution How to use your statistical calculator to calculate The mean The SD of a set of data points. The formula for the Variance (SD 2 ) The formula for the
More informationGROWTH HORMONE DEFICIENCY AND OTHER INDICATIONS FOR GROWTH HORMONE THERAPY CHILD AND ADOLESCENT
1. Medical Condition TUEC Guidelines GROWTH HORMONE DEFICIENCY AND OTHER INDICATIONS FOR GROWTH HORMONE THERAPY CHILD AND ADOLESCENT Growth Hormone Deficiency and other indications for growth hormone therapy
More informationInsulin-like growth factor-binding protein-1 in the prediction and development of type 2 diabetes in middle-aged Swedish men
Diabetologia (2008) 51:1135 1145 DOI 10.1007/s00125-008-1016-x ARTICLE Insulin-like growth factor-binding protein-1 in the prediction and development of type 2 diabetes in middle-aged Swedish men M. S.
More informationUsefulness and Limitation of Measurement of Insulin-Like Growth Factor Binding Protein-3 (IGFBP-3) for Diagnosis of Growth Hormone Deficiency
Endocrinol Japon 1992, 39 (6), 585-591 Usefulness and Limitation of Measurement of Insulin-Like Growth Factor Binding Protein-3 (IGFBP-3) for Diagnosis of Growth Hormone Deficiency YUKIHIRO HASEGAWA, TOMONOBU
More informationAbstract. Introduction CLINICAL STUDY
European Journal of Endocrinology (2006) 155 575 581 ISSN 0804-4643 CLINICAL STUDY Effects of short-term caloric restriction on circulating free IGF-I, acid-labile subunit, IGF-binding proteins (IGFBPs)-1
More informationMatthias M. Weber*, Beverly M.K. Biller, Birgitte Tønnes Pedersen, Effie Pournara, Jens Sandahl Christiansen and Charlotte H oybye**
Clinical Endocrinology (2017) 86, 192 198 doi: 10.1111/cen.13256 ORIGINAL ARTICLE The effect of growth hormone (GH) replacement on blood glucose homeostasis in adult nondiabetic patients with GH deficiency:
More informationDragana Miljic, 1 Predrag Miljic, 2 Mirjana Doknic, 1 Sandra Pekic, 1 Marina Djurovic, 1 Milica Colovic, 2 Vera Popovic 1. Research paper ABSTRACT
HORMONES 2006, 5(3):187-191 Research paper Changes in prothrombin and activated partial thromboplastin time during replacement therapy with human recombinant growth hormone in growth hormone deficient
More informationATHLETES & PRESCRIBING PHYSICIANS PLEASE READ
ATHLETES & PRESCRIBING PHYSICIANS PLEASE READ USADA can grant a Therapeutic Use Exemption (TUE) in compliance with the World Anti-Doping Agency International Standard for TUEs. The TUE application process
More informationAbstract. Introduction
European Journal of Endocrinology (1998) 138 70 75 Leptin concentrations in serum from a randomly recruited sample of 50- to 80-year-old men and women: positive association with plasma insulin-like growth
More informationHigh and Low GH: an update of diagnosis and management of GH disorders
High and Low GH: an update of diagnosis and management of GH disorders Georgia Chapter-AACE 2017 Laurence Katznelson, MD Professor of Medicine and Neurosurgery Associate Dean of Graduate Medical Education
More informationElevated Serum Levels of Adropin in Patients with Type 2 Diabetes Mellitus and its Association with
Elevated Serum Levels of Adropin in Patients with Type 2 Diabetes Mellitus and its Association with Insulin Resistance Mehrnoosh Shanaki, Ph.D. Assistant Professor of Clinical Biochemistry Shahid Beheshti
More informationKAZUE TAKANO, KAZUO SHIZUME, ITSURO HIBI and Members of Committee for the Treatment of Pituitary Dwarfism in Japan
Endocrinol. Japon. 1988, 35 (3), 477-484 A Comparison of Subcutaneous and Intramuscular Administration of Human Growth Hormone (hgh) and Increased Growth Rate by Daily Injection of hgh in GH Deficient
More informationImmunostaining was performed on tumor biopsy samples arranged in a tissue-microarray format or on
Supplemental Methods Immunohistochemical Analyses Immunostaining was performed on tumor biopsy samples arranged in a tissue-microarray format or on prostatectomy sections obtained post-study. Briefly,
More informationIncrease Growth Hormone by 701% after only 90 minutes...naturally
BREAKTHROUGH UNIVERSITY STUDY REVEALS Increase Growth Hormone by 701% after only 90 minutes...naturally Summary key points 275% increase in insulin 701% increase in growth hormone 300% increase in IGF1
More informationJournal of Biostatistics and Epidemiology
Journal of Biostatistics and Epidemiology Original Article Usage of statistical methods and study designs in publication of specialty of general medicine and its secular changes Swati Patel 1*, Vipin Naik
More informationPHARMACY POLICY STATEMENT Indiana Medicaid
DRUG NAME BILLING CODE BENEFIT TYPE SITE OF SERVICE ALLOWED COVERAGE REQUIREMENTS LIST OF DIAGNOSES CONSIDERED NOT MEDICALLY NECESSARY PHARMACY POLICY STATEMENT Indiana Medicaid Norditropin (somatropin)
More informationSubmitted: Accepted: Published online:
Neuroendocrinology Letters Volume 34 No. 3 2013 O R I G I N A L A R T I C L E Significant increase of IGF-I concentration and of IGF-I/IGFBP-3 molar ratio in generation test predicts the good response
More informationClinical Guideline POSITION STATEMENT ON THE INVESTIGATION AND TREATMENT OF GROWTH HORMONE DEFICIENCY IN TRANSITION
Clinical Guideline POSITION STATEMENT ON THE INVESTIGATION AND TREATMENT OF GROWTH HORMONE DEFICIENCY IN TRANSITION Date of First Issue 01/04/2015 Approved 28/01/2016 Current Issue Date 28/01/2016 Review
More informationPharmacokinetics and pharmacodynamics of anti-tuberculosis drugs in patients with tuberculosis
Pharmacokinetics and pharmacodynamics of anti-tuberculosis drugs in patients with tuberculosis Julie B Prahl, MD, PhD International Reference Laboratory of Mycobacteriology, Diagnostics and Infection Control
More informationGrowth hormone replacement does not increase serum prostate-specific antigen in hypopituitary men over 50 years
European Journal of Endocrinology (2002) 147 59 63 ISSN 0804-4643 CLINICAL STUDY Growth hormone replacement does not increase serum prostate-specific antigen in hypopituitary men over 50 years C W le Roux,
More informationDiabetologia 9 Springer-Verlag 1982
Diabetologia (1982) 22:333-337 Diabetologia 9 Springer-Verlag 1982 Kidney Function and Size in Type 1 (Insulin-Dependent) Diabetic Patients Before and During Growth Hormone Administration for One Week
More informationEileen Crimmins 1 Jianwei Hu 2 Peifeng Hu 3 Wei Huang 2 Jungki Kim 1 Yuhui Shi 2 John Strauss 1 Lu Zhang 1 Xiaohui Zhao 2 Yaohui Zhao 2
CHARLS Pilot: Blood-based Biomarker Documentation Eileen Crimmins 1 Jianwei Hu 2 Peifeng Hu 3 Wei Huang 2 Jungki Kim 1 Yuhui Shi 2 John Strauss 1 Lu Zhang 1 Xiaohui Zhao 2 Yaohui Zhao 2 June 2011 1 University
More informationAsian-Aust. J. Anim. Sci. Vol. 23, No. 3 : March 2010
366 Asian-Aust. J. Anim. Sci. Vol. 23, No. 3 : 366-371 March 2010 www.ajas.info Effects of Volatile Fatty Acids on IGF-I, IGFBP-3, GH, Insulin and Glucagon in Plasma, and IGF-I and IGFBP-3 in Different
More informationNo cases of precocious puberty were reported during clinical trials of risperidone in, cases of precocious puberty have been
levels than adults. The growth hormone elevations reported for the 12 patients with growth hormone excess were modest and well below levels reported in children with gigantism. 7,8 None of the patients
More informationReduced disorderliness of growth hormone release in biochemically inactive acromegaly after pituitary surgery
European Journal of Endocrinology (1998) 138 164 169 ISSN 0804-4643 Reduced disorderliness of growth hormone release in biochemically inactive acromegaly after pituitary surgery Gerrit van den Berg, Steven
More informationGrowth Hormone Therapy
Growth Hormone Therapy Policy Number: Original Effective Date: MM.04.011 05/21/1999 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 05/23/2014 Section: Prescription Drugs Place(s)
More informationcompared with t o Keywords: cycling; insulin-like growth factor; exercise; endurance; binding proteins
Br J Sports Med 21;35:33 37 33 Original articles Enfermería, Facultad de Medicina, Universidad Complutense, Madrid, J L Chicharro Fisiología A López-Calderon M A Villanúa Unidad de Investigación en Fisiología
More informationDevelopment of acromegaly in patients with prolactinomas
European Journal of Endocrinology (2003) 149 17 22 ISSN 0804-4643 CLINICAL STUDY Development of acromegaly in patients with prolactinomas Marianne Andersen, Casper Hagen, Jan Frystyk 1, Henrik Daa Schroeder
More informationPATIENTS WITH TYPE 1 diabetes show abnormalities in
0021-972X/04/$15.00/0 The Journal of Clinical Endocrinology & Metabolism 89(12):6305 6309 Printed in U.S.A. Copyright 2004 by The Endocrine Society doi: 10.1210/jc.2004-0572 Residual -Cell Function More
More informationHumatrope*, Norditropin*, Genotropin, Nutropin, Nutropin AQ, Omnitrope, Saizen
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.11 Subject: Growth Hormone Adult Page: 1 of 6 Last Review Date: December 8, 2017 Growth Hormone Adult
More informationDiabetologia 9 Springer-Verlag 1981
Diabetologia (1981) 2:451-456 Diabetologia 9 Springer-Verlag 1981 Originals Increased Kidney Size, Glomerular Filtration Rate and Renal Plasma Flow in Short-Term Insulin-Dependent Diabetics J. Sandahl
More informationHumatrope*, Norditropin*, Genotropin, Nutropin, Nutropin AQ, Omnitrope, Saizen
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.08.11 Subject: Growth Hormone Adult Page: 1 of 6 Last Review Date: September 15, 2016 Growth Hormone
More informationSUPPLEMENTARY DATA. Supplementary Table 1. Baseline Patient Characteristics
Supplementary Table 1. Baseline Patient Characteristics Normally distributed data are presented as mean (±SD), data that were not of a normal distribution are presented as median (ICR). The baseline characteristics
More informationISN Mission: Advancing the diagnosis, treatment and prevention of kidney diseases in the developing and developed world
ISN Mission: Advancing the diagnosis, treatment and prevention of kidney diseases in the developing and developed world Nutrition in Kidney Disease: How to Apply Guidelines to Clinical Practice? T. Alp
More informationGrowth hormone (GH) dose-dependent IGF-I response relates to pubertal height gain
Lundberg et al. BMC Endocrine Disorders (2015) 15:84 DOI 10.1186/s12902-015-0080-8 RESEARCH ARTICLE Growth hormone (GH) dose-dependent IGF-I response relates to pubertal height gain Open Access Elena Lundberg
More informationPAOLA DURAN, MD PEDIATRIC ENDOCRINOLOGIST CENPA, FCI COLOMBIA
PAOLA DURAN, MD PEDIATRIC ENDOCRINOLOGIST CENPA, FCI COLOMBIA GH has important effects on the intermediary metabolism of Carbohydrates Lipids Proteins Acute effects similar to insulin: hypoglycemia enhances
More informationGH Replacement Therapy in Growth Hormone Deficient Adults
GH Replacement Therapy in Growth Hormone Deficient Adults Sequence of hormone loss in hypopituitarism depending on location of a benign tumor Besser GM, Cudworth AG, eds. Clinical endocrinology: an illustrated
More informationIIGF-I and -II have potent mitogenic and metabolic
Phosphorylated Insulin-Like Growth Factor Binding Protein 1 Is Increased in Pregnant Diabetic S u b j e c t s J. Martin Gibson, Melissa Westwood, Finn F. Lauszus, Joachim G. Klebe, Allan Flyvbjerg, and
More informationShort boys treated with growth hormone show normal progression of testicular size and achieve normal serum testosterone concentrations
European Journal of Endocrinology (2002) 146 681 685 ISSN 0804-4643 CLINICAL STUDY Short boys treated with growth hormone show normal progression of testicular size and achieve normal serum testosterone
More informationAn audit of the insulin-tolerance test in 255 patients with pituitary disease
European Journal of Endocrinology (2002) 147 41 47 ISSN 0804-4643 CLINICAL STUDY An audit of the insulin-tolerance test in 255 patients with pituitary disease Martin Lange, Ole L Svendsen, Niels E Skakkebæk
More informationStudy of the correlation between growth hormone deficiency and serum leptin, adiponectin, and visfatin levels in adults
Study of the correlation between growth hormone deficiency and serum leptin, adiponectin, and visfatin levels in adults Z.-P. Li 1, M. Zhang 2, J. Gao 3, G.-Y. Zhou 3, S.-Q. Li 1 and Z.-M. An 3 1 Golden
More informationIT IS WELL known that uncoupling protein-1 (UCP1),
0021-972X/99/$03.00/0 Vol. 84, No. 11 The Journal of Clinical Endocrinology & Metabolism Printed in U.S.A. Copyright 1999 by The Endocrine Society Regulation of Uncoupling Protein-2 and -3 by Growth Hormone
More informationASSESSMENT OF QOL IN PATIENTS WITH PRADER WILLY SYNDROME
ASSESSMENT OF QOL IN PATIENTS WITH PRADER WILLY SYNDROME Aiming at investigating the relationship between QoL and clinical picture in patients with PWS, we conducted a multicentric study with prospective
More informationA Study on Type 2 Diabetes Mellitus Patients Using Regression Model and Survival Analysis Techniques
Available online at www.ijpab.com Shaik et al Int. J. Pure App. Biosci. 6 (1): 514-522 (2018) ISSN: 2320 7051 DOI: http://dx.doi.org/10.18782/2320-7051.5999 ISSN: 2320 7051 Int. J. Pure App. Biosci. 6
More informationUnitedHealthcare Pharmacy Clinical Pharmacy Programs
Program Number 2018 P 1039-8 Program UnitedHealthcare Pharmacy Clinical Pharmacy Programs Prior Authorization/Notification Human Growth Hormone, Growth Stimulating Products Medication Human Growth Hormone:
More informationEffects of sc Administration of Recombinant Human Insulin-Like Growth Factor I (IGF-I) on Normal Human Subjects
NOTE Effects of sc Administration of Recombinant Human Insulin-Like Growth Factor I (IGF-I) on Normal Human Subjects KAZUE TAKANOI,2, NAOMI HIZUKA1,2, KUMIKO ASAKAWA1,2 IZUMI SUKEGAWA1,2, KAZUO SHIZUME2
More informationAndrejs Kalvelis 1, MD, PhD, Inga Stukena 2, MD, Guntis Bahs 3 MD, PhD & Aivars Lejnieks 4, MD, PhD ABSTRACT INTRODUCTION. Riga Stradins University
CARDIOVASCULAR RISK FACTORS ORIGINAL ARTICLE Do We Correctly Assess the Risk of Cardiovascular Disease? Characteristics of Risk Factors for Cardiovascular Disease Depending on the Sex and Age of Patients
More informationSHORT COMMUNICATION. Diabetologia (2013) 56: DOI /s
Diabetologia (2013) 56:1542 1546 DOI 10.1007/s00125-013-2914-0 SHORT COMMUNICATION The pro-inflammatory biomarker soluble urokinase plasminogen activator receptor (supar) is associated with incident type
More informationDiagnosis of Growth Hormone Deficiency and Growth Hormone Stimulation Tests
Ranke MB (ed): Diagnostics of Endocrine Function in Children and Adolescents. Basel, Karger, 2003, pp 107 128 Diagnosis of Growth Hormone Deficiency and Growth Hormone Stimulation Tests Michael B. Ranke,
More informationChanges and clinical significance of serum vaspin levels in patients with type 2 diabetes
Changes and clinical significance of serum vaspin levels in patients with type 2 diabetes L. Yang*, S.J. Chen*, G.Y. Yuan, D. Wang and J.J. Chen Department of Endocrinology, Affiliated Hospital of Jiangsu
More informationIndividual Study Table Referring to Item of the Submission: Volume: Page:
2.0 Synopsis Name of Company: Abbott Laboratories Name of Study Drug: Meridia Name of Active Ingredient: Sibutramine hydrochloride monohydrate Individual Study Table Referring to Item of the Submission:
More informationHumatrope*, Norditropin*, Genotropin, Nutropin, Nutropin AQ, Omnitrope, Saizen, Zomacton (aka. Tev-Tropin)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.12 Subject: Growth Hormone Pediatric Page: 1 of 6 Last Review Date: September 15, 2016 Growth Hormone
More informationTHE EFFECT OF HIGH CALORIC DIET ON NUTRITIONAL PARAMETERS OF CHILDREN WITH THALASSAEMIA MAJOR.
THE EFFECT OF HIGH CALORIC DIET ON NUTRITIONAL PARAMETERS OF CHILDREN WITH THALASSAEMIA MAJOR. Ashraf T Soliman MD, PhD Professor of Pediatrics and Endocrinology Thalassemia Ht 102 cm HtSDS = -5.98 Transfusion
More informationUnitedHealthcare Pharmacy Clinical Pharmacy Programs
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2018 P 2016-8 Program Prior Authorization/Medical Necessity Medication Human Growth Hormone: Somatropin (Genotropin *, Humatrope *, Norditropin
More informationNOVO NORDISK A/S. 3. Pharmacotherapeutic group Somatropin is an endocrine hormone with metabolic and growth promoting effects. 4.
08-15 Norditropin NordiLet 10 mg/1.5 ml NOVO NORDISK A/S 1. Name of the medicinal product Norditropin NordiLet 10 mg/1.5 ml Pre-filled pen, solution for injection 2. Composition Norditropin NordiLet is
More information